PTH1-34: Phase I data

In a Phase I trial in 32 healthy postmenopausal women, 2.5 and 5 mg oral PTH1-34 containing 200 mg 5-CNAC achieved exposure and safety profiles similar to that of 20 ug subcutaneous Forteo teriparat...